1,5-ANHYDROGLUCITOL GLYCOMARK® (1,5-AG) ASSAY
Dual Vial Liquid Stable
The test is useful for a more informed diabetes treatment, providing unique information not obtainable with other tests.
GlycoMark (1,5-AG) reflects hyperglycemia above the renal threshold over the preceding 1-2 weeks which is complimentary to HbA1c and Glycated Serum Protein determinations. The test provides a useful, unique perspective of patient’s recent hyperglycemic excursions, which may not be evident from standard glycemic markers. Hyperglycemic excursions may be associated with glycemic variability, which can be investigated through more frequent self-monitoring of blood glucose (SMBG) or continuous glucose monitoring (CGM).
THE GLYCOMARK (1,5-AG) ASSAY ADVANTAGES
- Reveals recent deterioration in control not yet visible in HbA1c and glycated albumin
- Shows therapy change improvement within 2 weeks
- Can use fasting and non-fasting specimens
- There is no ordering frequency limitation so the test can be ordered as needed
- Reimbursed by Medicare, Medicaid, and most private payers
- Faster than HbA1c at assessing changes in glycemic control to changes in treatment program or patient non-adherence.
- Identify hyperglycemic excursions that may not be evident from standard glycemic markers.
- Reflective of glucose levels above the renal threshold (~180 mg/dL).
- Nearly 40% of diabetes patients in "good control" have significant glucose variability.
INTERPRETATION OF THE GLYCOMARK (1,5-AG) TEST RESULTS
- Abnormal 1,5-AG levels are an indicator of hyperglycemic episodes within the last 1-2 weeks, which may have occurred in the fasting state, post-meal state, or both.
- Changes in 1,5-AG levels reflect progression towards (increasing 1,5-AG) or away from (decreasing 1,5-AG) glycemic control.